On December 22, The Lancet published a study showing that it is pointless to take Merck & Co.'s antiviral covid drug molnupiravir because it does nothing to prevent hospitalization or death in higher-risk vaccinated adults.
The company claims the drug treats mild to moderate covid infection via twice-daily intake for five days within five days of symptom onset. The new paper, though, tells a much different story about this medically useless drug.
Between Dec. 8, 2021, and April 27, 2022, more than 25,700 eligible participants in the United Kingdom aged 50 or older – or 18 or older with relevant comorbidities – who got sick with covid within five days of taking part of the study agreed to receive either hospitalization or molnupiravir. The molnupiravir group took 800 milligrams (mg) of the drug twice daily for five days.
The mean age of participants was 56.6 and nearly all, 94 percent, had received at least three doses of a SARS-CoV-2 "vaccine" – meaning two primary mRNA (messenger RNA) shots and a "booster," or a single viral vector followed by two boosters.
At the conclusion of the study, a follow-up inquiry showed no statistically significant difference between the molnupiravir group and the hospitalization group in terms of the number of serious cases and deaths that occurred. The only difference is that the molnupiravir group supposedly recovered slightly faster than the hospitalization group.
"Twenty percent of the molnupiravir patients sought GP consultations compared to 24 percent of those who received usual care, a slight difference," reports explain. (Related: In animal experiments, molnupiravir was discovered to cause cancer.)
"Participants who received molnupiravir reported a median recovery time of nine days compared with 15 days for those only receiving usual care, the study found, with researchers stating that further analysis suggested that molnupiravir sped up recovery by 4.2 days on average."
National Institute for Health and Care Excellence urges covid patients not to take molnupiravir
Molnupiravir is so ineffective and medically useless that the National Institute for Health and Care Excellence (NICE) in the United Kingdom included it, along with four other drugs, on its list of covid remedies not to take.
NICE says that molnupiravir and the other four drugs should not be taken because "while there is some clinical evidence that they are effective at treating COVID-19 they were not found to be cost-effective."
In the UK, a five-day course of molnupiravir costs several hundred pounds, making it a lot more expensive than other remedies like ivermectin, which depending on the source costs just pennies per pill.
"Molnupiravir is a high-cost antiviral," said Richard Hobbs, one of the study's co-investigators. "Its deployment will depend on how much a mean four days’ improvement in symptoms will benefit the country."
Molnupiravir is so expensive that Merck generated for itself $5 billion in sales just within the first three quarters of 2022.
"I'd be afraid to take this or any drug that the medical establishment would prescribe," one commenter wrote. "Ivermectin is most likely completely safe. Not so for many drugs that doctors prescribe – both before and after this Covid man made illness and scare."
"They once had our complete trust. This and some other problems already caused by doctors have caused me to not trust them at all."
Another warned that the public should be wary of these kinds of drugs in the first place, describing them as the product of crafty "snake oil salesmanship" within the pharmaceutical industry.
"Just follow the FLCCC protocols and you will get better," said someone else about the Front Line COVID-19 Critical Care Alliance and its recommendations for healthy recovery. "It helps if you lose weight as well."
The latest news about covid can be found at Plague.info.
Sources for this article include:
Please contact us for more information.